Article

Adalimumab Biosimilar Launched for 1/5 Humira Price (in India)

The firm Cadila is launching its biosimilar Exemptia in India for about 1/5 the price tag of Abbot's Humira. Most biosimilars to date are sold at roughly two-thirds the cost of the FDA-approved versions.

According to a report from Reuters, the Indian pharmaceutical firm Cadila Healthcare Ltd. has launched a biosimilar version of adalimumab that will sell for 20% of the cost paid for Abbott's Humira in the United States.

The disappointingly high cost of many biosimilars compared to the already-approved drugs was a frequent topic of discussion at the recent annual meeting of the American College of Rheumatology in Boston. Prices of biosimilars to date are said to hover around 70% of the cost of the original drug.

According to a recent study published in Clinical Economics and Outcomes Research, based on Medicaid claims, the annual cost of treatment with Humira is $20,983.

Cadila has launched its biosimilar in India under the name Exemptia. Reportedly the company has scheduled talks with regulators in the US.

 

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
© 2024 MJH Life Sciences

All rights reserved.